One year after the 13 November attacks, the survey “Conditions de vie et Aspirations” (Living Conditions and Aspirations) by CRÉDOC (Research Centre for the Study and Monitoring of Living Standards), part of the 13 Novembre programme initiated by Inserm, CNRS and héSam Université, reports on the strong impact of the attacks on the French population, particularly the young.
A sample of 2,000 people representative of the French population responded to a series of questions such as “Can you say which terrorist acts, committed in the world or in France, have affected you most since the year 2000? What are the main consequences of the attacks that occurred on 13 November 2015?”
From this survey, we particularly learn that:
80% of French people say they have been marked by the attacks of 13 November 2015, even though three quarters of them have no personal link to the victims or places involved.
65% of 18-24 year olds and 63% of 25-39 year olds show strong feelings of fear, compared with 54% of people above that age range
The existence of cultural and religious tensions within society is the reason most often invoked to explain the attacks, and for nearly 40% of the population, they are inexplicable acts.
26% of French people have a personal link to the events (victim, witness, familiarity with the places), and 25% consider that there is too much talk about the 13 November.
Note: the interviews took place before the attacks in Nice on 14 July, and before those in Saint-Étienne de Rouvray on 26 July 2016.
Between November 2014 and November 2015, a study conducted by Inserm (Unit 912 SESSTIM – Economic and Social Sciences, Health Systems and Medical Informatics), Université Aix-Marseille, IRD, CNRS and the PACA Regional Health Observatory, trialed the unit-dose dispensing of certain antibiotics across ...
(Français) L’équipe VirPath du CIRI, en collaboration avec le laboratoire du Dr Guy Boivin (chaire de recherche du Canada sur les virus émergents, a développé et validé une stratégie innovante qui consiste à identifier et exploiter directement des échantillons infectieux prélevés cliniquement, ...